All Outputs (3)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. (2018)
Journal Article
ELEDRISI, M., SULEIMAN, N.N., SALAMEH, O., HAMAD, M.K., RABADI, O., MOHAMED, A., AL ADAWI, R. and SALAM, A. 2019. Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. Journal of clinical and translational endocrinology [online], 15, pages 35-36. Available from: https://doi.org/10.1016/j.jcte.2018.12.002

Insulin glargine is recombinant human insulin analog that is commonly used in patients with type 2 diabetes as well as those with type 1 diabetes. Pharmacokinetic and pharmacodynamics studies of insulin glargine had shown that it has an onset of acti... Read More about Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus..

Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. (2018)
Journal Article
JASSIM, Z., ELAJEZ, R., KHUDAIR, I., AL ANANY, R., AL-ADAWI, R.M. 2019. Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. Journal of pharmaceutical health services research [online], 10(1), pages 73-80. Available from: https://doi.org/10.1111/jphs.12240

Objective: Compare efficacy and safety of liraglutide (1.8 mg subcutaneous once daily) and exenatide (10 mcg subcutaneous twice daily) in uncontrolled type 2 diabetes at 26 and 52 weeks. Method: A retrospective observation study of uncontrolled type... Read More about Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study..

The impact of pharmacists’ input on the screening, management and prevention of metabolic syndrome. [Protocol] (2018)
Other
AL ADAWI, R., TONNA, A., STEWERT, D., RAYAN, C., ELEDRISI, M., and ABDELAZIZ, H. [2018]. The impact of pharmacists’ input on the screening, management and prevention of metabolic syndrome. [Protocol]. PROSPERO [online], item number CRD42018089862. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018089862

The aim of this research was to critically appraise, synthesise, and present the available evidence on the impact of pharmacists' input on the screening, prevention and management of metabolic syndrome (MetS). The specific aims were: 1) To determine... Read More about The impact of pharmacists’ input on the screening, management and prevention of metabolic syndrome. [Protocol].